Journal profile · Multiple
Neuro-Oncology Advances
ISSN 2632-2498 · Oxford University Press · United Kingdom
Neuro-Oncology Advances: CAS Zone 3 · Medicine (2025 upgraded edition); impact factor 5.9 (journal website); fully open access; APC about USD 2,489; median 132 days to acceptance (97 articles, last 24 months); 706 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Neuro-Oncology Advances is published by Oxford University Press and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Glioma Diagnosis and Treatment, Brain Metastases and Treatment and Meningioma and schwannoma management, together about 55.9% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
High-quality research on primary brain malignancies, noting that studies with negative outcomes are also valuable for the field and confirmatory studies are increasingly important. Brain metastases, cancer-related neurological events and advances in management of brain metastases and cancer in general to prevent brain metastases. Non-malignant nervous system tumors including meningiomas, schwannomas, pituitary tumors, spinal and peripheral nerve tumors. Technological advances in surgery, radiation therapy, radiosurgery and imaging Bioinformatics and computational advances in large data analyses related to subjects within our scope. Spinal tumors and spine metastases.
From the journal's Aims & Scope
Research area (LetPub): Multiple
Editor-in-chief Wolfgang WickPublisher website
Editorial board by country: none in mainland China; most named United States 15, Germany 8, Canada 6, Netherlands 3, Hong Kong, China 2 (43 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Glioma Diagnosis and TreatmentMedicine32%
- Brain Metastases and TreatmentMedicine18.4%
- Meningioma and schwannoma managementMedicine5.5%
- Radiomics and Machine Learning in Medical ImagingMedicine5.1%
- Lung Cancer Research StudiesMedicine3.2%
- Neurofibromatosis and Schwannoma CasesMedicine3.1%
- Cancer, Hypoxia, and MetabolismBiochemistry, Genetics and Molecular Biology2.8%
- Radiopharmaceutical Chemistry and ApplicationsMedicine2.6%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Clinical Neurology | Zone 3 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Clinical Neurology | Zone 3 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
PMCPublisher website
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher) 2025
- 5.9Publisher website ·
- 5-year impact factor (publisher) 2025
- 4.4Publisher website ·
- CiteScore 2026-06
- 5.9LetPub ·
- CiteScore (publisher) 2025
- 5.9Publisher website ·
- SJR 2026-06
- 1.42LetPub ·
- SNIP 2026-06
- 1.07LetPub ·
- h-index
- 50OpenAlex ·
- i10-index
- 503OpenAlex ·
- 2-year mean citedness
- 1.14OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 211LetPub ·
- Downloads per year (publisher) 2025
- 539,202Publisher website ·
Articles by year OpenAlex count · 3,932 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 404 | 404 | 93 |
| 2025 | 706 | 706 | 482 |
| 2024 | 523 | 523 | 1,287 |
| 2023 | 541 | 541 | 2,261 |
| 2022 | 390 | 390 | 2,709 |
| 2021 | 612 | 612 | 4,054 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
132 daysMedian, submission to acceptance · P25–P75 97 days – 207 days
- Acceptance to online
- median 7 days (97 articles)
- Submission to online
- median 145 days
- Sample
- 97 articles with submission and acceptance dates (564 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 12 weeksLetPub ·
- Submission to first decision 2025
- 36 daysPublisher website ·
- Submission to final decision 2025
- 76 daysPublisher website ·
- Acceptance to publication
- 13 daysPublisher website ·
- Submission to publication (journal-reported)
- about 12 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 2,489 | Yes | CC BY, CC BY-NC | |
| OpenAlex | USD 2,615 | — | — | |
| LetPub | USD 2,489 | Yes | — |
Other charges and waivers (author guidelines)
- Submission fee
- USD 3,625
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare7 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- ≤ 5
- Reference style
- Numbered, in order of citation
- Suggested reviewers
- Optional
- Highlights
- Required
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted14, with length limits
- advances-in-briefReviews, Advances-in-Brief, and Editorials that cover subjects of timely interest and importance to cancer researchers.Length not stated
- basic and translational investigationsBasic and Translational Investigations or Clinical Investigations that report original experimental, translational, clinical, epidemiological, quality-of-life, …Length not stated
- brief communicationThe following types of unsolicited articles are published in Neuro-Oncology Advances : Basic and Translational Investigations or Clinical Investigations that re…Length not stated
- brief communicationsBrief Communications report on a study presenting brief, unpublished results or technical notes.Length not stated
- case reportThe following types of unsolicited articles are published in Neuro-Oncology Advances : Basic and Translational Investigations or Clinical Investigations that re…Length not stated
- clinical investigationsBasic and Translational Investigations or Clinical Investigations that report original experimental, translational, clinical, epidemiological, quality-of-life, …Length not stated
- editorialThe following types of unsolicited articles are published in Neuro-Oncology Advances : Basic and Translational Investigations or Clinical Investigations that re…main text ≤ 1,000 words
- editorialsReviews, Advances-in-Brief, and Editorials that cover subjects of timely interest and importance to cancer researchers.Length not stated
- letter to the editorThe following types of unsolicited articles are published in Neuro-Oncology Advances : Basic and Translational Investigations or Clinical Investigations that re…Length not stated
- metadata analyses/reviewsMetadata Analyses/Reviews based on detailed systematic analyses of clinical trials and studies that clearly delineate novel findings or solidify previously less…Length not stated
- molecular tumor board case reportsMolecular Tumor Board Case Reports highlight cases of rare and/or difficult diagnoses where an integrative approach, using conventional and new genome diagnosti…Length not stated
- reviewThe following types of unsolicited articles are published in Neuro-Oncology Advances : Basic and Translational Investigations or Clinical Investigations that re…Length not stated
- reviewsReviews, Advances-in-Brief, and Editorials that cover subjects of timely interest and importance to cancer researchers.Length not stated
- technical noteThe following types of unsolicited articles are published in Neuro-Oncology Advances : Basic and Translational Investigations or Clinical Investigations that re…Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, Open access, Preprints, Self-archiving
- AI use
AI authorship policy Model summary
Natural language processing tools driven by artificial intelligence (AI) do not qualify as authors, and the Journal will screen for them in author lists.
Source ↗Publisher website ·- Authorship Authorship
Authorship criteria Model summary
All authors listed on the manuscript should have contributed significantly to the experimental design, its implementation, or analysis and interpretation of the data. All authors should have been involved in the writing of the manuscript at draft and any revision stages, and have read and approved the final version. More than one first author may be indicated by footnotes; however, we ask authors …
Source ↗Publisher website ·- Conflicts of interest Conflict of Interest
Conflict of interest declaration Model summary
All conflicts of interest (or relationships that would be suspected of constituting conflicts) should be declared and explained at the end of the manuscript text at the time of submission and should reflect not only current conflicts (extending back 36 months) but those in place at the time the research was conducted. All authors must declare any conflicts of interest. It is the responsibility of …
Source ↗Publisher website ·- Data availability Data Availability
Data availability encouragement Model summary
Neuro-Oncology Advances strongly encourages authors to make all deidentified data and software code on which the conclusions of the paper rely available to readers. Data presented in the manuscript or additional supplementary files should be deposited in a public repository whenever possible (see below under the manuscript Methods section). Authors may be asked to make available the underlying dei…
Source ↗Publisher website ·- Publication ethics Publication Ethics
COPE member Model summary
Neuro-Oncology Advances and Oxford University Press are members of the Committee on Publication Ethics (COPE) and follow the guidance provided in the COPE Core Practices. Neuro-Oncology Advances also subscribes to the International Committee of Medical Journal Editors (ICJME) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly work in Medical Journals. It is expected t…
Source ↗Publisher website ·- Open access Open access charge
Book review charge 3625 USD Society membership discount 20% Total 0 USD Charges are quoted based on the information provided. The Low and Middle Income Countries discount is applied prior to any other discount. Please note that these prices are subject to change. All stated charges are exclusive of any applicable value added tax, goods and services tax and any similar sales or excise taxes (Sales …
Source ↗Publisher website ·- Preprints Preprint Policy
Preprint policy Model summary
Authors retain the right to make an Author’s Original Version (preprint) available through various channels, and this does not prevent submission to the Journal. For further information see our Online Licensing, Copyright and Permissions policies. If accepted, the authors are required to update the status of any preprint, including your published paper’s DOI, as described on our Author Self-Archiv…
Source ↗Publisher website ·- Self-archiving Self-archiving of unpublished manuscript
Authors may upload their submitted manuscript to an online repository or website such as BioRxiv.
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Oxford University Press
- Country or region
- United Kingdom
- Language
- English
- ISSN
- 2632-2498
- Latest issue on the website
- Volume 8, Issue 1 (December 2026)
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Author guidelines ↗LetPub
- Aims & Scope ↗LetPub
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗LetPub
- Editorial board ↗LetPub
FAQ
Frequently asked questions about Neuro-Oncology Advances
What CAS zone is Neuro-Oncology Advances in?
In the 2025 upgraded edition of the CAS Journal Ranking, Neuro-Oncology Advances is in Zone 3 of Medicine, and in Zone 3 of the minor category Clinical Neurology / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Neuro-Oncology Advances?
The journal's website gives an impact factor of 5.9 (2025); this is the journal's own figure, as LetPub lists none for it; CiteScore 5.9, h-index 50.
How long does peer review take at Neuro-Oncology Advances?
Based on the dates recorded on 97 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 132 days (interquartile range 97–207 days); authors report an average review time of about 12 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Neuro-Oncology Advances?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: ≤ 5; Reference style: Numbered, in order of citation; Suggested reviewers: Optional; Highlights: Required; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Neuro-Oncology Advances based?
Of the 43 board members whose country the journal's board page names, none are in mainland China; the countries named most often are United States (15), Germany (8) and Canada (6). Counted from the institutions listed on the board page; for reference only.
Which databases index Neuro-Oncology Advances?
According to LetPub and DOAJ records, Neuro-Oncology Advances is indexed in ESCI, Scopus and DOAJ. The journal's website also lists PMC; that list has not been checked against each database.
Is Neuro-Oncology Advances open access, and what is the APC?
Neuro-Oncology Advances is a fully open-access journal. APC about USD 2,489.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .